ENOV ENOVIS CORPORATION

Enovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

Enovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

Wilmington, DE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that Brady Shirley, President and COO, Ben Berry, CFO, and Louis Vogt, Group President Recon will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 5:30pm p.m. ET (2:30 p.m. PT) on Monday, February 12, 2024.

A link to the live audio webcast, as well as a replay of this event, will be available on the company’s website at Events and Presentations.      

ABOUT ENOVIS

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV.  For more information about Enovis, please visit .

Contact:

Kyle Rose

Vice President, Investor Relations

Enovis Corporation





EN
07/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Enovis Announces Third Quarter 2025 Results

Enovis Announces Third Quarter 2025 Results Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today annou...

 PRESS RELEASE

Enovis announces webcast and conference call for Third Quarter 2025 Re...

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch